MedPath

Feasibility of Docetaxel-cisplatin as 3rd or 4th line treatment for recurrent or unresectable biliary tract cacner.

Not Applicable
Recruiting
Conditions
Biliary tract cancer
Registration Number
JPRN-UMIN000009212
Lead Sponsor
yokohama city university graduated school of medicine Department of Gastroenterological Surgery
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

If patients reject.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to progression
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath